Rosonabant

Rosonabant is a pharmaceutical drug that was developed by the Sanofi-Aventis company. It was initially designed as an antidepressant, but was later found to have potential in the treatment of obesity, smoking cessation, and alcohol abuse. However, due to concerns about its side effects, it was withdrawn from the market in 2008.

History

Rosonabant was first developed by the French pharmaceutical company Sanofi-Aventis. It was initially intended to be an antidepressant, but during clinical trials, it was found to have potential in treating obesity, smoking cessation, and alcohol abuse. The drug was approved for use in the European Union in 2006, but was withdrawn from the market in 2008 due to concerns about its side effects.

Mechanism of Action

Rosonabant works by blocking the CB1 receptor, a part of the endocannabinoid system in the brain that is involved in the regulation of appetite and the sensation of pleasure. By blocking this receptor, Rosonabant reduces the desire to eat and the pleasure derived from smoking and drinking alcohol.

Side Effects

The most common side effects of Rosonabant include nausea, dizziness, and depression. In some cases, the drug can also cause serious psychiatric side effects, including suicidal thoughts. These side effects led to the withdrawal of the drug from the market in 2008.

Current Status

Since its withdrawal, Rosonabant has been the subject of ongoing research. Some studies suggest that it may have potential in the treatment of other conditions, such as Parkinson's disease and Alzheimer's disease, but further research is needed to confirm these findings.

See Also

• CB1 receptor
• Endocannabinoid system
• Sanofi-Aventis

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

• 
  Rosonabant